View Item 

Show simple item record

Neuropharmacology in Pediatric Brain Injury: A Review
dc.contributor.authorPangilinan, Percival H.
dc.contributor.authorGiacoletti‐argento, Angela
dc.contributor.authorShellhaas, Renee
dc.contributor.authorHurvitz, Edward A.
dc.contributor.authorHornyak, Joseph Edward
dc.date.accessioned2019-01-15T20:27:15Z
dc.date.available2019-01-15T20:27:15Z
dc.date.issued2010-12
dc.identifier.citationPangilinan, Percival H.; Giacoletti‐argento, Angela ; Shellhaas, Renee; Hurvitz, Edward A.; Hornyak, Joseph Edward (2010). "Neuropharmacology in Pediatric Brain Injury: A Review." PM&R 2(12): 1127-1140.
dc.identifier.issn1934-1482
dc.identifier.issn1934-1563
dc.identifier.urihttps://hdl.handle.net/2027.42/146985
dc.publisherWiley Periodicals, Inc.
dc.titleNeuropharmacology in Pediatric Brain Injury: A Review
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelKinesiology and Sports
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI
dc.contributor.affiliationumDepartment of Physical Medicine and Rehabilitation, University of Michigan, 325 E. Eisenhower, Ann Arbor, MI 48108
dc.contributor.affiliationumDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI
dc.contributor.affiliationumDivision of Pediatric Neurology, Department of Pediatrics, University of Michigan, Ann Arbor, MI
dc.contributor.affiliationumDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146985/1/pmr21127.pdf
dc.identifier.doi10.1016/j.pmrj.2010.07.007
dc.identifier.sourcePM&R
dc.identifier.citedreferenceM.L. Michals, M.L. Crismon, S. Roberts, A. Childs. Clozapine response and adverse effects in nine brainâ injured patients. J Clin Psychopharmacol. 1993; 13: 198 â 203.
dc.identifier.citedreferenceA.F.T. Arnsten. Stimulants: therapeutic Actions in ADHD. Neuropsychopharmacology. 2006; 31: 2376 â 2383.
dc.identifier.citedreferenceC.T. Gualtieri, R.W. Evans. Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury. Brain Inj. 1988; 2: 273 â 290.
dc.identifier.citedreferenceS.E. Williams, M.D. Ris, R. Ayyangar, B.K. Schefft, D. Berch. Recovery in pediatric brain injury: is psychostimulant medication beneficial?. J Head Trauma Rehabil. 1998; 13: 73 â 81.
dc.identifier.citedreferenceD.M. Mahalick, P.W. Carmel, J.P. Greenberg, et al. Psychopharmacologic treatment of acquired attention disorders in children with brain injury. Pediatr Neurosurg. 1998; 29: 121 â 126.
dc.identifier.citedreferenceT.E. Wilens, J. Biederman, J. Wong, T.J. Spencer, J.B. Prince. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol. 2000; 10: 217 â 222.
dc.identifier.citedreferenceT.E. Wilens, J. Waxmonsky, M. Scott, et al. An open trial of adjunctive donepezil in attentionâ deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005; 15: 947 â 955.
dc.identifier.citedreferenceR.L. Doyle, J. Frazier, T.J. Spencer, D. Geller, J. Biederman, T. Wilens. Donepezil in the treatment of ADHDâ like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006; 9: 543 â 549.
dc.identifier.citedreferenceJ.A. Bourgeois, N. Bahadur, S. Minjares. Donepezil for cognitive deficits following traumatic brain injury: a case report. J Neuropsychiatry Clin Neurosci. 2002; 14: 463 â 464.
dc.identifier.citedreferenceM. Foster, D.R. Spiegel. Use of donepezil in the treatment of cognitive impairments of moderate traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2008; 20: 106.
dc.identifier.citedreferenceJ. Ballesteros, I. Güemes, N. Ibarra, J.I. Quemada. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J Head Trauma Rehabil. 2008; 23: 171 â 180.
dc.identifier.citedreferenceO. Tenovuo. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injuryâ clinical experience in 111 patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29: 61 â 67.
dc.identifier.citedreferenceJ.R. Fann, W.J. Katon, J.M. Uomoto, P.C. Esselman. Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. Am J Psychiatry. 1995; 152: 1493 â 1499.
dc.identifier.citedreferenceL. Himanen, R. Portin, O. Tenovuo, et al. Attention and depressive symptoms in chronic phase after traumatic brain injury. Brain Inj. 2009; 23: 220 â 227.
dc.identifier.citedreferenceS. Koponen, T. Taiminen, R. Portin, et al. Axis I and II psychiatric disorders after traumatic brain injury: a 30â year followâ up study. Am J Psychiatry. 2002; 159: 1315 â 1321.
dc.identifier.citedreferenceR.E. Jorge, R.G. Robinson, D. Moser, A. Tateno, B. Crespoâ Facorro, S. Arndt. Major depression following traumatic brain injury. Arch Gen Psychiatry. 2004; 61: 42 â 50.
dc.identifier.citedreferenceD.B. Arciniegas, J.M. Silver. Pharmacotherapy of posttraumatic cognitive impairments. Behav Neurol. 2006; 17: 25 â 42.
dc.identifier.citedreferenceJ.R. Fann, J.M. Uomoto, W.J. Katon. Cognitive improvement with treatment of depression following mild traumatic brain injury. Psychosomatics. 2001; 42: 48 â 54.
dc.identifier.citedreferenceB.A. Wroblewski, K. McColgan, K. Smith, J. Whyte, W.D. Singer. The incidence of seizures during tricyclic antidepressant drug treatment in a brainâ injured population. J Clin Psychopharmacol. 1990; 10: 124 â 128.
dc.identifier.citedreferenceD.L. Warden, B. Gordon, T.W. McAllister, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. 2006; 23: 1468 â 1501.
dc.identifier.citedreferenceR.F. Bessette, L.G. Peterson. Fluoxetine and organic mood syndrome. Psychosomatics. 1992; 33: 224 â 226.
dc.identifier.citedreferenceS.A. Horsfield, R.B. Rosse, V. Tomasino, B.L. Schwartz, J. Mastropaolo, S.I. Deutsch. Fluoxetine’s effects on cognitive performance in patients with traumatic brain injury. Int J Psychiatry Med. 2002; 32: 337 â 344.
dc.identifier.citedreferenceJ.A. Schmitt, M.J. Kruizinga, W.J. Riedel. Nonâ serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol. 2001; 15: 173 â 179.
dc.identifier.citedreferenceA.J. Schneier, B.J. Shields, S.G. Hostetler, H. Xiang, G.A. Smith. Incidence of pediatric traumatic brain injury and associated hospital resource utilization in the United States. Pediatrics. 2006; 118: 483 â 492.
dc.identifier.citedreferenceForum on Child and Family Statistics, http://childstats.gov, Accessed August 1, 2010.
dc.identifier.citedreferenceC.Y. Crooks, J.M. Zumsteg, K.R. Bell. Traumatic brain injury: a review of practice management and recent advances. Phys Med Rehabil Clin N Am. 2007; 18: 681 â 710, vi.
dc.identifier.citedreferenceJ. Hugh, R. Raghupathi. New concepts in treatment of pediatric traumatic brain injury. Anesthesiol Clin. 2009; 27: 213 â 240.
dc.identifier.citedreferenceT. Priestley, A.L. Horne, R.M. McKernan, J.A. Kemp. The effect of NMDA receptor glycine site antagonists on hypoxiaâ induced neurodegeneration of rat cortical cell cultures. Brain Res. 1990; 531: 183 â 188.
dc.identifier.citedreferenceC. Ikonomidou, L. Turski. Prevention of traumaâ induced neurodegeneration in infant and adult rat brain: glutamate antagonists. Metab Brain Dis. 1996; 11: 125 â 141.
dc.identifier.citedreferenceV.L. Rao, A. Dogan, K.G. Todd, K.K. Bowen, R.J. Dempsey. Neuroprotection by memantine, a nonâ competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res. 2001; 911: 96 â 100.
dc.identifier.citedreferenceD. Pohl, P. Bittigau, M.J. Ishimaru, et al. Nâ methylâ Dâ aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci U S A. 1999; 96: 2508 â 2513.
dc.identifier.citedreferenceK.W. Muir. Glutamateâ based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol. 2006; 6: 53 â 60.
dc.identifier.citedreferenceC. Ikonomidou, L. Turski. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol. 2002; 1: 383 â 386.
dc.identifier.citedreferenceJ.A. Kemp, R.M. McKernan. NMDA receptor pathways as drug targets. Nat Neurosci. 2002; 5 (Suppl): 1039 â 1042.
dc.identifier.citedreferenceM. Fujiki, T. Kubo, T. Kamida, et al. Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholineâ receptor activator, on rats with concussive mild traumatic brain injury. J Clin Neurosci. 2008; 15: 791 â 796.
dc.identifier.citedreferenceM. Fujiki, H. Kobayashi, S. Uchida, R. Inoue, K. Ishii. Neuroprotective effect of donepezil, a nicotinic acetylcholineâ receptor activator, on cerebral infarction in rats. Brain Res. 2005; 1043: 236 â 241.
dc.identifier.citedreferenceK.D. Statler. Pediatric posttraumatic seizures: epidemiology, putative mechanisms of epileptogenesis and promising investigational progress. Dev Neurosci. 2006; 28: 354 â 363.
dc.identifier.citedreferenceP.D. Adelson, S.L. Bratton, N.A. Carney, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 19. The role of antiâ seizure prophylaxis following severe pediatric traumatic brain injury. Pediatr Crit Care Med. 2003; 4 (Suppl): S72 â S75.
dc.identifier.citedreferenceA. Chiaretti, R. De Benedictis, G. Polidori, M. Piastra, A. Iannelli, C. Di Rocco. Early postâ traumatic seizures in children with head injury. Childs Nerv Syst. 2000; 16: 862 â 866.
dc.identifier.citedreferenceJ.P. Szaflarski, K.S. Sangha, C.J. Lindsell, L.A. Shutter. Prospective, randomized, singleâ blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010; 12: 165 â 172.
dc.identifier.citedreferenceH. Wang, J. Gao, T.F. Lassiter, et al. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care. 2006; 5: 71 â 78.
dc.identifier.citedreferenceH. Klitgaard, A. Pitkanen. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 2003; 5 (Suppl 1): S9 â S16.
dc.identifier.citedreferenceO.L. Alves, A.J. Doyle, T. Clausen, C. Gilman, R. Bullock. Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. Ann N Y Acad Sci. 2003; 993: 25 â 34, discussion 48â 53.
dc.identifier.citedreferenceR.C. Hoover, M. Motta, J. Davis, et al. Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma. 2004; 21: 501 â 512.
dc.identifier.citedreferenceV. Tang, J. Warden, N. Cullen, E. Rutledge. Topiramate in traumatic brain injury: adverse effects on cognitive function. J Head Trauma Rehabil. 2007; 22: 409 â 410.
dc.identifier.citedreferenceO.T. Dolberg, G. Barkai, Y. Gross, S. Schreiber. Differential effects of topiramate in patients with traumatic brain injury and obesityâ a case series. Psychopharmacology (Berl). 2005; 179: 838 â 845.
dc.identifier.citedreferenceC.M. McDonald, K.M. Jaffe, G.C. Fay, et al. Comparison of indices of traumatic brain injury severity as predictors of neurobehavioral outcome in children. Arch Phys Med Rehabil. 1994; 75: 328 â 337.
dc.identifier.citedreferenceE.A. Fridman, J. Calvar, M. Bonetto, et al. Fast awakening from minimally conscious state with apomorphine. Brain Inj. 2009; 23: 172 â 177.
dc.identifier.citedreferenceF.Y. Aoki, D.S. Sitar. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988; 14: 35 â 51.
dc.identifier.citedreferenceL.B. Green, J.E. Hornyak, E.A. Hurvitz. Amantadine in pediatric patients with traumatic brain injury: a retrospective, caseâ controlled study. Am J Phys Med Rehabil. 2004; 83: 893 â 897.
dc.identifier.citedreferenceM.A. McMahon, J.N. Vargusâ Adams, L.J. Michaud, J. Bean. Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. Am J Phys Med Rehabil. 2009; 88: 525 â 532.
dc.identifier.citedreferenceP.D. Patrick, J.A. Blackman, J.L. Mabry, M.L. Buck, M.J. Gurka, M.R. Conaway. Dopamine agonist therapy in lowâ response children following traumatic brain injury. J Child Neurol. 2006; 21: 879 â 885.
dc.identifier.citedreferenceP.D. Patrick, M.L. Buck, M.R. Conaway, J.A. Blackman. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj. 2003; 17: 497 â 506.
dc.identifier.citedreferenceM.A. Passler, R.V. Riggs. Positive outcomes in traumatic brain injuryâ vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil. 2001; 82: 311 â 315.
dc.identifier.citedreferenceJ.E. Hornyak, V.S. Nelson, E.A. Hurvitz. The use of methylphenidate in paediatric traumatic brain injury. Pediatr Rehabil. 1997; 1: 15 â 17.
dc.identifier.citedreferenceR.P. Clauss, W.M. Güldenpfennig, H.W. Nel, M.M. Sathekge, R.R. Venkannagari. Extraordinary arousal from semiâ comatose state on zolpidem. A case report. S Afr Med J. 2000; 90: 68 â 72.
dc.identifier.citedreferenceR. Clauss, W. Nel. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation. 2006; 21: 23 â 28.
dc.identifier.citedreferenceS.I. Cohen, T.T. Duong. Increased arousal in a patient with anoxic brain injury after administration of zolpidem. Am J Phys Med Rehabil. 2008; 87: 229 â 231.
dc.identifier.citedreferenceJ. Whyte, R. Myers. Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil. 2009; 88: 410 â 418.
dc.identifier.citedreferenceZ. Kawecki, S. Kwiatkowski, P. Grzegorzewski, I. Szlachta Jezioro. Sudden improvement of all neurological functions after general anesthesia and twoâ day intrathecal infusion of baclofen in a child with primary brainâ stem injury [in Polish]. Przegl Lek. 2007; 64 (Suppl 2): 13 â 14.
dc.identifier.citedreferenceM. Sarà, F. Pistoia, E. Mura, P. Onorati, S. Govoni. Intrathecal baclofen in patients with persistent vegetative state: 2 hypotheses. Arch Phys Med Rehabil. 2009; 90: 1245 â 1249.
dc.identifier.citedreferenceM. Sarà, S. Sacco, F. Cipolla, et al. An unexpected recovery from permanent vegetative state. Brain Inj. 2007; 21: 101 â 103.
dc.identifier.citedreferenceT. Taira, T. Hori. Intrathecal baclofen in the treatment of postâ stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl. 2007; 97: 227 â 229.
dc.identifier.citedreferenceA.H. Lequerica, L.J. Rapport, K. Loeher, B.N. Axelrod, S.J. Vangel Jr, R.A. Hanks. Agitation in acquired brain injury: impact on acute rehabilitation therapies. J Head Trauma Rehabil. 2007; 22: 177 â 183.
dc.identifier.citedreferenceL.P. Fugate, L.A. Spacek, L.A. Kresty, C.E. Levy, J.C. Johnson, W.J. Mysiw. Definition of agitation following traumatic brain injury: I. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil. 1997; 78: 917 â 923.
dc.identifier.citedreferenceW.J. Mysiw, R.D. Jackson, J.D. Corrigan. Amitriptyline for postâ traumatic agitation. Am J Phys Med Rehabil. 1988; 67: 29 â 33.
dc.identifier.citedreferenceS. Fleminger, R.J. Greenwood, D.L. Oliver. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2006; (4), CD003299.
dc.identifier.citedreferenceG.E. Francisco, W.C. Walker, N.D. Zasler, M.H. Bouffard. Pharmacological management of neurobehavioural sequelae of traumatic brain injury: a survey of current physiatric practice. Brain Inj. 2007; 21: 1007 â 1014.
dc.identifier.citedreferenceL.B. Goldstein. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry. 1995; 58: 753 â 755.
dc.identifier.citedreferenceB.A. Wroblewski, A.B. Joseph. The use of intramuscular midazolam for acute seizure cessation or behavioral emergencies in patients with traumatic brain injury. Clin Neuropharmacol. 1992; 15: 44 â 49.
dc.identifier.citedreferenceR. Perna. Benzodiazepines and antipsychotics: cognitive side effects. J Head Trauma Rehabil. 2004; 19: 516 â 518.
dc.identifier.citedreferenceL.B. Goldstein. Basic and clinical studies of pharmacologic effects on recovery from brain injury. J Neural Transplant Plast. 1993; 4: 175 â 192.
dc.identifier.citedreferenceB.A. Cotton, K.B. Snodgrass, S.B. Fleming, et al. Betaâ blocker exposure is associated with improved survival after severe traumatic brain injury. J Trauma. 2007; 62: 26 â 33, discussion 33â 35.
dc.identifier.citedreferenceM.M. Brooke, D.R. Patterson, K.A. Questad, D. Cardenas, L. Farrelâ Roberts. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil. 1992; 73: 917 â 921.
dc.identifier.citedreferenceT.L. Massagli. Neurobehavioral effects of phenytoin, carbamazepine, and valproic acid: implications for use in traumatic brain injury. Arch Phys Med Rehabil. 1991; 72: 219 â 226.
dc.identifier.citedreferenceE.H. Kossoff, G.K. Bergey, J.M. Freeman, E.P. Vining. Levetiracetam psychosis in children with epilepsy. Epilepsia. 2001; 42: 1611 â 1613.
dc.identifier.citedreferenceH.P. Bootsma, A.P. Aldenkamp, L. Diepman, et al. The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia. 2006; 47 (Suppl 2): 24 â 27.
dc.identifier.citedreferenceP.E. Chatham Showalter, D.N. Kimmel. Agitated symptom response to divalproex following acute brain injury. J Neuropsychiatry Clin Neurosci. 2000; 12: 395 â 397.
dc.identifier.citedreferenceB.A. Wroblewski, A.B. Joseph, J. Kupfer, K. Kalliel. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj. 1997; 11: 37 â 47.
dc.identifier.citedreferenceP.E. Chathamâ Showalter. Carbamazepine for combativeness in acute traumatic brain injury. J Neuropsychiatry Clin Neurosci. 1996; 8: 96 â 99.
dc.identifier.citedreferenceP. Azouvi, C. Jokic, N. Attal, P. Denys, S. Markabi, B. Bussel. Carbamazepine in agitation and aggressive behaviour following severe closedâ head injury: results of an open trial. Brain Inj. 1999; 13: 797 â 804.
dc.identifier.citedreferenceA. Pachet, S. Friesen, D. Winkelaar, S. Gray. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Inj. 2003; 17: 715 â 722.
dc.identifier.citedreferenceA. Cipriani, C. Santilli, T.A. Furukawa, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; (2), CD006532.
dc.identifier.citedreferenceL.P. Fugate, L.A. Spacek, L.A. Kresty, C.E. Levy, J.C. Johnson, W.J. Mysiw. Measurement and treatment of agitation following traumatic brain injury: II. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil. 1997; 78: 924 â 928.
dc.identifier.citedreferenceD.L. Reinhard, J. Whyte, M.E. Sandel. Improved arousal and initiation following tricyclic antidepressant use in severe brain injury. Arch Phys Med Rehabil. 1996; 77: 80 â 83.
dc.identifier.citedreferenceR.D. Jackson, J.D. Corrigan, J.A. Arnett. Amitriptyline for agitation in head injury. Arch Phys Med Rehabil. 1985; 66: 180 â 181.
dc.identifier.citedreferenceL. Turnerâ Stokes, N. Hassan, K. Pierce, F. Clegg. Managing depression in brain injury rehabilitation: the use of an integrated care pathway and preliminary report of response to sertraline. Clin Rehabil. 2002; 16: 261 â 268.
dc.identifier.citedreferenceJ.M. Silver, T.W. McAllister, D.B. Arciniegas. Depression and cognitive complaints following mild traumatic brain injury. Am J Psychiatry. 2009; 166: 653 â 661.
dc.identifier.citedreferenceT.A. Ashman, J.B. Cantor, W.A. Gordon, et al. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury. Arch Phys Med Rehabil. 2009; 90: 733 â 740.
dc.identifier.citedreferenceH. Lee, S.W. Kim, J.M. Kim, I.S. Shin, S.J. Yang, J.S. Yoon. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Hum Psychopharmacol. 2005; 20: 97 â 104.
dc.identifier.citedreferenceJ.R. Fann, J.M. Uomoto, W.J. Katon. Sertraline in the treatment of major depression following mild traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2000; 12: 226 â 232.
dc.identifier.citedreferenceR. Kant, L. Smithâ Seemiller, D. Zeiler. Treatment of aggression and irritability after head injury. Brain Inj. 1998; 12: 661 â 666.
dc.identifier.citedreferenceJ.M. Meythaler, L. Depalma, M.J. Devivo, S. Guinâ Renfroe, T.A. Novack. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj. 2001; 15: 321 â 331.
dc.identifier.citedreferenceR.D. Zafonte, N. Cullen, J. Lexell. Serotonin agents in the treatment of acquired brain injury. J Head Trauma Rehabil. 2002; 17: 322 â 334.
dc.identifier.citedreferenceU. Müller, T. Murai, T. Bauerâ Wittmund, D.Y. von Cramon. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj. 1999; 13: 805 â 811.
dc.identifier.citedreferenceR.L. Sloan, K.W. Brown, B. Pentland. Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj. 1992; 6: 315 â 319.
dc.identifier.citedreferenceA.E. Kline, A.N. Hoffman, J.P. Cheng, R.D. Zafonte, J.L. Massucci. Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. Neurosci Lett. 2008; 448: 263 â 267.
dc.identifier.citedreferenceA.E. Kline, J.L. Massucci, R.D. Zafonte, C.E. Dixon, J.R. DeFeo, E.H. Rogers. Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma. Crit Care Med. 2007; 35: 919 â 924.
dc.identifier.citedreferenceA.N. Hoffman, J.P. Cheng, R.D. Zafonte, A.E. Kline. Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injuryâ induced deficits. Life Sci. 2008; 83: 602 â 607.
dc.identifier.citedreferenceS.W. Stanislav. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj. 1997; 11: 335 â 341.
dc.identifier.citedreferenceE.P. Elovic, R. Lansang, Y. Li, J.H. Ricker. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil. 2003; 18: 177 â 195.
dc.identifier.citedreferenceD.M. Gardner, R.J. Baldessarini, P. Waraich. Modern antipsychotic drugs: a critical overview. CMAJ. 2005; 172: 1703 â 1711.
dc.identifier.citedreferenceJ. Horacek, V. Bubenikovaâ Valesova, M. Kopecek, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006; 20: 389 â 409.
dc.identifier.citedreferenceD.B. Allison, J.L. Mentore, M. Heo, et al. Antipsychoticâ induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156: 1686 â 1696.
dc.identifier.citedreferenceR. Wilkinson, J.M. Meythaler, S. Guinâ Renfroe. Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj. 1999; 13: 1025 â 1031.
dc.identifier.citedreferenceV. Kadyan, S.C. Colachis, M.J. Depalma, J.D. Sanderson, W.J. Mysiw. Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation. Brain Inj. 2003; 17: 631 â 637.
dc.identifier.citedreferenceS.N. Caroff, S.C. Mann. Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77: 185 â 202.
dc.identifier.citedreferenceC.J. Bellamy, S.L. Kaneâ Gill, B.A. Falcione, A.L. Seybert. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma. 2009; 66: 954 â 958.
dc.identifier.citedreferenceS.W. Stanislav, A. Childs. Evaluating the usage of droperidol in acutely agitated persons with brain injury. Brain Inj. 2000; 14: 261 â 265.
dc.identifier.citedreferenceJ.W. Newcomer. Secondâ generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19 (Suppl 1): 1 â 93.
dc.identifier.citedreferenceE. Noé, J. Ferri, C. Trénor, J. Chirivella. Efficacy of ziprasidone in controlling agitation during postâ traumatic amnesia. Behav Neurol. 2007; 18: 7 â 11.
dc.identifier.citedreferenceL.K. Scott, R. Green, P.J. McCarthy, S.A. Conrad. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. J Neurosurg Pediatr. 2009; 3: 484 â 487.
dc.identifier.citedreferenceE. Kim, M. Bijlani. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2006; 18: 547 â 549.
dc.identifier.citedreferenceT.J. Oster, C.A. Anderson, C.M. Filley, H.S. Wortzel, D.B. Arciniegas. Quetiapine for mania due to traumatic brain injury. CNS Spectr. 2007; 12: 764 â 769.
dc.identifier.citedreferenceJ.P. Daniels, A. Felde. Quetiapine treatment for mania secondary to brain injury in 2 patients. J Clin Psychiatry. 2008; 69: 497 â 498.
dc.identifier.citedreferenceM.S. Wilson, C.J. Gibson, R.J. Hamm. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil. 2003; 82: 871 â 879.
dc.identifier.citedreferenceH.S. Levin, G. Hanten. Executive functions after traumatic brain injury in children. Pediatr Neurol. 2005; 33: 79 â 93.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pmr21127.pdf
Size:
181.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.